Cancer Monoclonal Antibodies Market Developments by 2031
The Cancer Monoclonal Antibodies Market is expected to register a CAGR of 18% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
This report studies the Cancer Monoclonal Antibodies Market on basis of Application, Type, and Region. The country analysis provides the major markets worldwide. With the market estimates, in US dollars (US$), the report describes the trends, drivers, and challenges in the market. It can be used by all stakeholders who want to gain an edge and make the right decisions in the monoclonal antibody market.
Purpose of the ReportThe report Cancer Monoclonal Antibodies Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Cancer Monoclonal Antibodies Market Segmentation
Type- Murine Antibodies
- Chimeric Antibodies
- Humanized Antibodies
- Bevacizumab
- Rituximab
- Trastuzumab
- Cetuximab
- Panitumumab
- Other Monoclonal Antibody Therapies
- Breast Cancer
- Blood Cancer
- Liver Cancer
- Brain Cancer
- Colorectal Cancer
- Lung Cancer
Strategic Insights
Cancer Monoclonal Antibodies Market Growth Drivers- Rising Cancer Rates and Aging Populations:Globally rising cancer incidence & aging population are major reasons behind the cancer monoclonal antibodies market. In 2020 alone, more than 18 million new cancer cases were reported worldwide, according to the American Cancer Society – and that number will continue to rise in the coming years. Monoclonal antibodies, with their ability to treat specific cancer but with fewer side-effects than chemo, have emerged as the go-to drug for cancers including breast, lung and colon cancer. The cancer rates are increasing and thus the need for highly effective agents such as monoclonal antibodies is increasing, which fuels blood bank market growth.
- Technology of Antibody Engineering and Design:Innovations in antibody engineering (eg, creating bispecific antibodies or antibody-drug conjugates (ADCs)), likewise propel the market. Such advances augment the specificity and effectiveness of monoclonal antibodies and thus make it possible to use these to fight cancer. The FDA-approved bispecific antibody Blincyto, for instance, has been a huge success against leukemia. New antibody technologies are helping cancer patients, according to the National Cancer Institute (NCI), and they are raising the need for monoclonal antibodies to combat cancer.
- Rising Investment in Cancer Research: Increased funding and investment in cancer research by governments, pharmaceutical companies, and private organizations have accelerated the development of new cancer treatments, including monoclonal antibodies. Research into cancer immunotherapy and targeted therapies is helping to identify new targets for monoclonal antibody drugs.
- Cancer Treatment, Precision Medicine, and the Future of Cancer Therapy:
One of the biggest trends that is likely to influence the cancer monoclonal antibodies market in the future is the transformation to targeted cancer therapy with precision medicine. Precision medicine develops treatments based on the patient’s genetic information so that more specific treatments can be administered. In the case of patients with cancer, monoclonal antibodies are being used in combination with genomic profiling to develop tailored treatment regimens. Molecular diagnostics and tailored treatment will rise and precision medicine will be more than 11 percent more profitable every year by 2020, says the National Institutes of Health (NIH). This is the trend that will propel important monoclonal antibody treatments and clinical use of them.
- Combination Therapies for Enhanced Efficacy:
We are now seeing the era of combination therapies in cancer care, where monoclonal antibodies complement another treatment like chemotherapy, immunotherapy or targeted therapy. Combination therapies are improving in the trials, particularly for rare and hard-to-treat cancers. Combining monoclonal antibodies with immune checkpoint inhibitors, for example, have been promising at encouraging immune responses to cancer. Combination immunotherapies are the current gold standard in cancer treatment, with monoclonal antibodies increasingly appearing in combination treatments, as the European Society for Medical Oncology (ESMO) says. - Focus on Immuno-oncology: Immuno-oncology is one of the most significant trends in cancer treatment. Monoclonal antibodies, as a form of immunotherapy, are being increasingly studied for their ability to stimulate the immune system to recognize and destroy cancer cells.
- Expanding in Emerging Markets: Cancer, whose incidence in emerging markets is rising, is another huge opportunity in the monoclonal antibodies market. Asia-Pacific, Latin America and the Middle East all have increasing cancer incidences but have better healthcare systems and better treatments. As these countries are developing healthcare infrastructure, monoclonal antibodies market size and share will increase. Cancer is the second leading cause of death in low- and middle-income countries, the WHO states, so monoclonal antibody therapies are needed.
- Explosion of Biosimilars in Cancer Therapy: Increasing use and approval of biosimilars in the treatment of cancer is another major growth driver for the cancer monoclonal antibodies market. Biosimilars are biologic drugs very similar to reference monoclonal antibodies, but cheaper. The rise of biosimilars should also lower the price of cancer therapies, particularly in low- and middle-income countries. While patents on blockbuster monoclonal antibodies such as Rituxan and Herceptin are expiring, biosimilars are becoming available to increase market share. The FDA says there are now a total of 560 approved biosimilars and this will keep driving the treatment options and the blood bank market growth.
- Developing mAbs for Rare Cancers: There is a growing opportunity to develop monoclonal antibodies for rare cancers, which often have limited treatment options and are under-researched. By focusing on rare cancers, biotech companies can address an underserved market.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Cancer Monoclonal Antibodies Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Cancer Monoclonal Antibodies Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The market is expected to register a CAGR of 18% during 2023–2031.
Cancer monoclonal antibodies market is driven by the increasing incidence of cancer, ageing population, and improved antibody engineering (binary antibodies, antibody-drug conjugates) which provide better cures for cancer.
New development in cancer monoclonal antibodies market will be precision medicine based individual therapy and rising number of combination therapies, improving effectiveness and extending the scope of monoclonal antibody therapy.
Key players in this market are - Amgen Inc, Thermo Fisher Scientific Inc, F Hoffmann La Roche Ltd, Bristol Myers Squibb Company, GlaxoSmithKline Plc, Johnson and Johnson Services Inc, Novartis AG, Eli Lilly and Company, Spectrum Pharmaceuticals Inc
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Cancer Monoclonal Antibodies Market - By Type
1.3.2 Cancer Monoclonal Antibodies Market - By Therapies
1.3.3 Cancer Monoclonal Antibodies Market - By Application
1.3.4 Cancer Monoclonal Antibodies Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CANCER MONOCLONAL ANTIBODIES MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CANCER MONOCLONAL ANTIBODIES MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CANCER MONOCLONAL ANTIBODIES MARKET - GLOBAL MARKET ANALYSIS
6.1. CANCER MONOCLONAL ANTIBODIES - GLOBAL MARKET OVERVIEW
6.2. CANCER MONOCLONAL ANTIBODIES - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. CANCER MONOCLONAL ANTIBODIES MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. MURINE ANTIBODIES
7.3.1. Overview
7.3.2. Murine Antibodies Market Forecast and Analysis
7.4. CHIMERIC ANTIBODIES
7.4.1. Overview
7.4.2. Chimeric Antibodies Market Forecast and Analysis
7.5. HUMANIZED ANTIBODIES
7.5.1. Overview
7.5.2. Humanized Antibodies Market Forecast and Analysis
8. CANCER MONOCLONAL ANTIBODIES MARKET - REVENUE AND FORECASTS TO 2028 - THERAPIES
8.1. OVERVIEW
8.2. THERAPIES MARKET FORECASTS AND ANALYSIS
8.3. BEVACIZUMAB
8.3.1. Overview
8.3.2. Bevacizumab Market Forecast and Analysis
8.4. RITUXIMAB
8.4.1. Overview
8.4.2. Rituximab Market Forecast and Analysis
8.5. TRASTUZUMAB
8.5.1. Overview
8.5.2. Trastuzumab Market Forecast and Analysis
8.6. CETUXIMAB
8.6.1. Overview
8.6.2. Cetuximab Market Forecast and Analysis
8.7. PANITUMUMAB
8.7.1. Overview
8.7.2. Panitumumab Market Forecast and Analysis
8.8. OTHER MONOCLONAL ANTIBODY THERAPIES
8.8.1. Overview
8.8.2. Other Monoclonal Antibody Therapies Market Forecast and Analysis
9. CANCER MONOCLONAL ANTIBODIES MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
9.1. OVERVIEW
9.2. APPLICATION MARKET FORECASTS AND ANALYSIS
9.3. BREAST CANCER
9.3.1. Overview
9.3.2. Breast Cancer Market Forecast and Analysis
9.4. BLOOD CANCER
9.4.1. Overview
9.4.2. Blood Cancer Market Forecast and Analysis
9.5. LIVER CANCER
9.5.1. Overview
9.5.2. Liver Cancer Market Forecast and Analysis
9.6. BRAIN CANCER
9.6.1. Overview
9.6.2. Brain Cancer Market Forecast and Analysis
9.7. COLORECTAL CANCER
9.7.1. Overview
9.7.2. Colorectal Cancer Market Forecast and Analysis
9.8. LUNG CANCER
9.8.1. Overview
9.8.2. Lung Cancer Market Forecast and Analysis
9.9. OTHERS
9.9.1. Overview
9.9.2. Others Market Forecast and Analysis
10. CANCER MONOCLONAL ANTIBODIES MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Cancer Monoclonal Antibodies Market Overview
10.1.2 North America Cancer Monoclonal Antibodies Market Forecasts and Analysis
10.1.3 North America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Type
10.1.4 North America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Therapies
10.1.5 North America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Application
10.1.6 North America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Countries
10.1.6.1 United States Cancer Monoclonal Antibodies Market
10.1.6.1.1 United States Cancer Monoclonal Antibodies Market by Type
10.1.6.1.2 United States Cancer Monoclonal Antibodies Market by Therapies
10.1.6.1.3 United States Cancer Monoclonal Antibodies Market by Application
10.1.6.2 Canada Cancer Monoclonal Antibodies Market
10.1.6.2.1 Canada Cancer Monoclonal Antibodies Market by Type
10.1.6.2.2 Canada Cancer Monoclonal Antibodies Market by Therapies
10.1.6.2.3 Canada Cancer Monoclonal Antibodies Market by Application
10.1.6.3 Mexico Cancer Monoclonal Antibodies Market
10.1.6.3.1 Mexico Cancer Monoclonal Antibodies Market by Type
10.1.6.3.2 Mexico Cancer Monoclonal Antibodies Market by Therapies
10.1.6.3.3 Mexico Cancer Monoclonal Antibodies Market by Application
10.2. EUROPE
10.2.1 Europe Cancer Monoclonal Antibodies Market Overview
10.2.2 Europe Cancer Monoclonal Antibodies Market Forecasts and Analysis
10.2.3 Europe Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Type
10.2.4 Europe Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Therapies
10.2.5 Europe Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Application
10.2.6 Europe Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Cancer Monoclonal Antibodies Market
10.2.6.1.1 Germany Cancer Monoclonal Antibodies Market by Type
10.2.6.1.2 Germany Cancer Monoclonal Antibodies Market by Therapies
10.2.6.1.3 Germany Cancer Monoclonal Antibodies Market by Application
10.2.6.2 France Cancer Monoclonal Antibodies Market
10.2.6.2.1 France Cancer Monoclonal Antibodies Market by Type
10.2.6.2.2 France Cancer Monoclonal Antibodies Market by Therapies
10.2.6.2.3 France Cancer Monoclonal Antibodies Market by Application
10.2.6.3 Italy Cancer Monoclonal Antibodies Market
10.2.6.3.1 Italy Cancer Monoclonal Antibodies Market by Type
10.2.6.3.2 Italy Cancer Monoclonal Antibodies Market by Therapies
10.2.6.3.3 Italy Cancer Monoclonal Antibodies Market by Application
10.2.6.4 Spain Cancer Monoclonal Antibodies Market
10.2.6.4.1 Spain Cancer Monoclonal Antibodies Market by Type
10.2.6.4.2 Spain Cancer Monoclonal Antibodies Market by Therapies
10.2.6.4.3 Spain Cancer Monoclonal Antibodies Market by Application
10.2.6.5 United Kingdom Cancer Monoclonal Antibodies Market
10.2.6.5.1 United Kingdom Cancer Monoclonal Antibodies Market by Type
10.2.6.5.2 United Kingdom Cancer Monoclonal Antibodies Market by Therapies
10.2.6.5.3 United Kingdom Cancer Monoclonal Antibodies Market by Application
10.2.6.6 Rest of Europe Cancer Monoclonal Antibodies Market
10.2.6.6.1 Rest of Europe Cancer Monoclonal Antibodies Market by Type
10.2.6.6.2 Rest of Europe Cancer Monoclonal Antibodies Market by Therapies
10.2.6.6.3 Rest of Europe Cancer Monoclonal Antibodies Market by Application
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Cancer Monoclonal Antibodies Market Overview
10.3.2 Asia-Pacific Cancer Monoclonal Antibodies Market Forecasts and Analysis
10.3.3 Asia-Pacific Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Type
10.3.4 Asia-Pacific Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Therapies
10.3.5 Asia-Pacific Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Application
10.3.6 Asia-Pacific Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Cancer Monoclonal Antibodies Market
10.3.6.1.1 Australia Cancer Monoclonal Antibodies Market by Type
10.3.6.1.2 Australia Cancer Monoclonal Antibodies Market by Therapies
10.3.6.1.3 Australia Cancer Monoclonal Antibodies Market by Application
10.3.6.2 China Cancer Monoclonal Antibodies Market
10.3.6.2.1 China Cancer Monoclonal Antibodies Market by Type
10.3.6.2.2 China Cancer Monoclonal Antibodies Market by Therapies
10.3.6.2.3 China Cancer Monoclonal Antibodies Market by Application
10.3.6.3 India Cancer Monoclonal Antibodies Market
10.3.6.3.1 India Cancer Monoclonal Antibodies Market by Type
10.3.6.3.2 India Cancer Monoclonal Antibodies Market by Therapies
10.3.6.3.3 India Cancer Monoclonal Antibodies Market by Application
10.3.6.4 Japan Cancer Monoclonal Antibodies Market
10.3.6.4.1 Japan Cancer Monoclonal Antibodies Market by Type
10.3.6.4.2 Japan Cancer Monoclonal Antibodies Market by Therapies
10.3.6.4.3 Japan Cancer Monoclonal Antibodies Market by Application
10.3.6.5 South Korea Cancer Monoclonal Antibodies Market
10.3.6.5.1 South Korea Cancer Monoclonal Antibodies Market by Type
10.3.6.5.2 South Korea Cancer Monoclonal Antibodies Market by Therapies
10.3.6.5.3 South Korea Cancer Monoclonal Antibodies Market by Application
10.3.6.6 Rest of Asia-Pacific Cancer Monoclonal Antibodies Market
10.3.6.6.1 Rest of Asia-Pacific Cancer Monoclonal Antibodies Market by Type
10.3.6.6.2 Rest of Asia-Pacific Cancer Monoclonal Antibodies Market by Therapies
10.3.6.6.3 Rest of Asia-Pacific Cancer Monoclonal Antibodies Market by Application
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Cancer Monoclonal Antibodies Market Overview
10.4.2 Middle East and Africa Cancer Monoclonal Antibodies Market Forecasts and Analysis
10.4.3 Middle East and Africa Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Type
10.4.4 Middle East and Africa Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Therapies
10.4.5 Middle East and Africa Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Application
10.4.6 Middle East and Africa Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Cancer Monoclonal Antibodies Market
10.4.6.1.1 South Africa Cancer Monoclonal Antibodies Market by Type
10.4.6.1.2 South Africa Cancer Monoclonal Antibodies Market by Therapies
10.4.6.1.3 South Africa Cancer Monoclonal Antibodies Market by Application
10.4.6.2 Saudi Arabia Cancer Monoclonal Antibodies Market
10.4.6.2.1 Saudi Arabia Cancer Monoclonal Antibodies Market by Type
10.4.6.2.2 Saudi Arabia Cancer Monoclonal Antibodies Market by Therapies
10.4.6.2.3 Saudi Arabia Cancer Monoclonal Antibodies Market by Application
10.4.6.3 U.A.E Cancer Monoclonal Antibodies Market
10.4.6.3.1 U.A.E Cancer Monoclonal Antibodies Market by Type
10.4.6.3.2 U.A.E Cancer Monoclonal Antibodies Market by Therapies
10.4.6.3.3 U.A.E Cancer Monoclonal Antibodies Market by Application
10.4.6.4 Rest of Middle East and Africa Cancer Monoclonal Antibodies Market
10.4.6.4.1 Rest of Middle East and Africa Cancer Monoclonal Antibodies Market by Type
10.4.6.4.2 Rest of Middle East and Africa Cancer Monoclonal Antibodies Market by Therapies
10.4.6.4.3 Rest of Middle East and Africa Cancer Monoclonal Antibodies Market by Application
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Cancer Monoclonal Antibodies Market Overview
10.5.2 South and Central America Cancer Monoclonal Antibodies Market Forecasts and Analysis
10.5.3 South and Central America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Type
10.5.4 South and Central America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Therapies
10.5.5 South and Central America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Application
10.5.6 South and Central America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Cancer Monoclonal Antibodies Market
10.5.6.1.1 Brazil Cancer Monoclonal Antibodies Market by Type
10.5.6.1.2 Brazil Cancer Monoclonal Antibodies Market by Therapies
10.5.6.1.3 Brazil Cancer Monoclonal Antibodies Market by Application
10.5.6.2 Argentina Cancer Monoclonal Antibodies Market
10.5.6.2.1 Argentina Cancer Monoclonal Antibodies Market by Type
10.5.6.2.2 Argentina Cancer Monoclonal Antibodies Market by Therapies
10.5.6.2.3 Argentina Cancer Monoclonal Antibodies Market by Application
10.5.6.3 Rest of South and Central America Cancer Monoclonal Antibodies Market
10.5.6.3.1 Rest of South and Central America Cancer Monoclonal Antibodies Market by Type
10.5.6.3.2 Rest of South and Central America Cancer Monoclonal Antibodies Market by Therapies
10.5.6.3.3 Rest of South and Central America Cancer Monoclonal Antibodies Market by Application
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. CANCER MONOCLONAL ANTIBODIES MARKET, KEY COMPANY PROFILES
13.1. AMGEN INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. THERMO FISHER SCIENTIFIC INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. F. HOFFMANN-LA ROCHE LTD
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. BRISTOL-MYERS SQUIBB COMPANY
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. GLAXOSMITHKLINE PLC
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. JOHNSON AND JOHNSON SERVICES, INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. NOVARTIS AG
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ELI LILLY AND COMPANY
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. SPECTRUM PHARMACEUTICALS, INC.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. PFIZER INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. Amgen Inc.
2. Thermo Fisher Scientific Inc.
3. F. Hoffmann-La Roche Ltd
4. Bristol-Myers Squibb Company
5. GlaxoSmithKline Plc
6. Johnson and Johnson Services, Inc.
7. Novartis AG
8. Eli Lilly and Company
9. Spectrum Pharmaceuticals, Inc.
10. Pfizer Inc
11. Genmab
12. Seattle Genetics
13. Takeda Pharmaceutical Company Ltd
14. Fresenius Kabi AG,
15. Sanofi
16. AstraZeneca Plc
17. Abbvie Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For